Emma Barroso Fernández
Investigador post-doc
I finished my Biology studies at the University of Barcelona in 2003. In 2006 I completed an Experimental Master in Pharmacy in the Pharmacology department under the supervision of Dr. Manuel Vázquez Carrera. A year later, in 2007, Dr. Vázquez Carrera gave me the opportunity to start my doctoral studies with a scholarship funded by the Bosch i Gimpera Institute. In January 2011 I obtained my title of Excellent Cum Laude PhD with the work entitled "Efecte de l'activació de PPARβ/δ sobre l'oxidació d'àcids grassos i el procés inflamatori" from which two original articles emerged (Endocrinology 2011 and Biochemichal Pharmacology 2011) with an impact index of 4,459 and 4,705 respectively and belonging to Q1.
Subsequently, from February 2011 to the present I have been part of the research team of Dr. Vázquez Carrera with a Research Staff contract by CIBERDEM (Ciber for Diabetes and Metabolic Diseases, ISCIII) where I have dedicated myself to the study of molecular pathways involved in hyperlipidemia, inflammation and insulin resistance being some of the most relevant works: Molecular Metabolism 2018, Diabetes 2016, Biochimica et Biophysica Acta 2015 and Biochemica et Biophysica acta 2013. Also during this time I have collaborated with other research teams of which original publications have also emerged (Petrov et at. Biochimica et Biophysica Acta 2015, Pedros et at. Biochimica et Biophysica Acta 2014 i Vilà et al. PlosOne 2012).
On the other hand, since 2016 I am also a 3 + 3 Associate Professor at the University of Barcelona teaching classes in the Pharmacognosy subject.
Professional network profiles
Last Publications
- Rostami A, Palomer FX, Pizarro J, Barroso E, Valenzuela-Alcaraz BI, Fàtima Crispi Brillas, Nistal JF, Hurlé MA, García R, Wahli W and Vazquez M PPARß/d prevents inflammation and fibrosis during diabetic cardiomyopathy. PHARMACOLOGICAL RESEARCH . 210: 107515-107515.
- Barroso E, Jurado-Aguilar J, Wahli W, Palomer FX and Vazquez M Increased hepatic gluconeogenesis and type 2 diabetes mellitus. TRENDS IN ENDOCRINOLOGY AND METABOLISM . 35(12): 1062-1077.
- Guardiola M, Girona J, Barroso E, García-Altares M, Ibarretxe D, Plana N, Ribalta J, Correig X, Vazquez M, Masana L and Rodríguez-Calvo R The GDF15 3' UTR Polymorphism rs1054564 Is Associated with Diabetes and Subclinical Atherosclerosis. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES . 25(22): .
News
-
New Therapeutic Targets to Fight Type 2 Diabetes
A study led by Dr Manuel Vázquez-Carreras presents an integrative view of the most outstanding advances in understanding this process and helping to identify new pharmacological targets in the fight against type 2 diabetes mellitus.
-
CDF15 cytokine, a promising therapeutic target against type 2 diabetes
A team led by Dr. Manuel Vázquez-Carrera, from the Institut de Recerca Sant Joan de Déu and professor Faculty of Pharmacy and Food Sciences and the Institute of Biomedicine (IBUB) of the UB, has conducted a review study on the Growth Differentiation Factor 15 (GDF15) -a protein expressed under physiological stress conditions- and its potential impact on the treatment for type 2 diabetes.